Huntington's Disease Clinical Trials Corner: June 2019

Filipe B Rodrigues, Joaquim J Ferreira, Edward J Wild, Filipe B Rodrigues, Joaquim J Ferreira, Edward J Wild

Abstract

In this edition of the Huntington's Disease Clinical Trials Corner we expand on the HD-DBS and on the TRIHEP3 trials, and we list all currently registered and ongoing clinical trials in Huntington's disease.

Trial registration: ClinicalTrials.gov NCT02519036 NCT03761849 NCT02535884 NCT02453061.

Keywords: Huntington disease; clinical trials.

Conflict of interest statement

FBR and EJW were sub-investigators on LEGATO-HD (NCT02215616), IONIS HTTRx (NCT02519036) and IONIS HTTRx OLE (NCT03342053), and are sub-investigators on the Roche GENERATION-HD (NCT03761849), Roche Natural History Study (NCT03664804) and Roche GEN-EXTEND (NCT03842969) trials, and EJW was a sub-investigator on the Amaryllis (NCT02197130). EJW is the chief investigator of the Roche GEN-PEAK trial (NCT04000594) and FBR is a sub-investigator. JJF was principal investigator on LEGATO-HD and on a trial of ethyl-eicosapentanoate in Huntington’s disease. The authors did not make use of confidential or privileged information: all materials included in this manuscript were collected from publicly available sources. FBR has provided consultancy services to GLG. EJW has participated in scientific advisory boards with Hoffmann-La Roche Ltd, Ionis, Shire, GSK, Wave Life Sciences, PTC Therapeutics, Takeda and Mitoconix. All honoraria were paid through UCL Consultants Ltd, a wholly owned subsidiary of UCL. Their Host Institution, University College London Hospitals NHS Foundation Trust, has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals. Hoffman La Roche Ltd has supported UCL with research funding for EJW. In view of the support to both regular authors from Hoffman-La Roche Ltd, JJF was invited to be a co-author to ensure the sections on the Ionis/Roche program were suitably balanced.

JJF received grants from GlaxoSmithKline, Grunenthal, Fundação MSD (Portugal), TEVA, MSD, Allergan, Novartis, Medtronic. He received consultancy fees from GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, BIAL, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion Pharmaceuticals. He is employed by Faculdade de Medicina de Lisboa and CNS - Campus Neurológico Sénior. He also participated in advisory boards for Bial and expert testimony to Novartis.

References

    1. Heinrich-Heine University, KKS Netzwerk, Medtronic, The George Huntington Institute, EHDN, CHDI Foundation Inc. Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington’s Disease (HD). ; 2014.
    1. Institut National de la Santé Et de la Recherche Médicale, Ultragenyx Pharmaceutical Inc. A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington’s Disease. ; 2015.
    1. Rodrigues FB, Wild EJ. Clinical trials corner: September 2017. J Huntingtons Dis. 2017;6(3):255–63.
    1. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with huntington’s disease. The New England Journal of Medicine. 2019.
    1. Hoffmann-La Roche. A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington’s Disease. ; 2018.
    1. Ionis Pharmaceuticals I. Study in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139. ; 2017.
    1. Hoffmann-La Roche. Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington’s Disease. ; 2018.
    1. Hoffmann-La Roche. An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington’s Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies. ; 2019.
    1. Hoffmann-La Roche. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139). ; 2017.
    1. Hoffmann-La Roche. A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington’s Disease. ; 2019.
    1. Wojtecki L, Groiss SJ, Hartmann CJ, Elben S, Omlor S, Schnitzler A, et al. Deep brain stimulation in huntington’s disease-preliminary evidence on pathophysiology, efficacy and safety. Brain Sci. 2016;6(3):38.
    1. Wojtecki L, Groiss SJ, Ferrea S, Elben S, Hartmann CJ, Dunnett SB, et al. A prospective pilot trial for pallidal deep brain stimulation in huntington’s disease. Front Neurol. 2015;6:177.
    1. Gonzalez V, Cif L, Biolsi B, Garcia-Ptacek S, Seychelles A, Sanrey E, et al. Deep brain stimulation for Huntington’s disease: Long-term results of a prospective open-label study. Journal of Neurosurgery. 2014;121(1):114–22.
    1. Mochel F. Triheptanoin for the treatment of brain energy deficit: A 14-year experience. Journal of Neuroscience Research. 2017;95(11):2236–43.
    1. Travessa AM, Rodrigues FB, Mestre TA, Ferreira JJ. Fifteen years of clinical trials in huntington’s disease: A very low clinical drug development success rate. Journal of Huntington’s Disease. 2017;6(2):157–63.
    1. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, et al. Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry. 1995;152(12):1771–5.
    1. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al. A controlled trial of idebenone in Huntington’s disease. Movement Disorders: Official Journal of the Movement Disorder Society. 1996;11(5):549–54.
    1. Huntington Study Group. A randomized placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397–404.
    1. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology. 2005;65(2):286–92.
    1. Huntington Study Group T-HDI, Dorsey ER, Shoulson I, Leavitt B, Ross C, Beck CA, et al. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study. Archives of Neurology. 2008;65(12):1582–9.
    1. Ferreira JJ, Rosser A, Craufurd D, Squitieri F, Mallard N, Landwehrmeyer B. Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: A placebo-controlled clinical trial. Movement Disorders: Official Journal of the Movement Disorder Society. 2015;30(10):1426–9.
    1. Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, et al. PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014;82(10):850–7.
    1. Hersch SM, Schifitto G, Oakes D, Bredlau A-L, Meyers CM, Nahin R, et al. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. 2017;89(6):594–601.
    1. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006;66(2):250–2.
    1. Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Heron B, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016;87(5):550–3.
    1. Mochel F, Duteil S, Marelli C, Jauffret C, Barles A, Holm J, et al. Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington’s disease. European Journal of Human Genetics: EJHG. 2010;18(9):1057–60.
    1. Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, et al. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015;84(5):490–5.
    1. Rodrigues FB, Wild EJ. Huntingtons disease clinical trials corner: February 2018. Journal of Huntington’s Disease. 2018;7(1):89–98.
    1. Rodrigues FB, Wild EJ. Huntington’s disease clinical trials corner: August 2018. J Huntingtons Dis. 2018;7(3):279–86.
    1. Rodrigues FB, Quinn L, Wild EJ. Huntington’s disease clinical trials corner: January 2019. Journal of Huntington’s Disease. 2019;8(1):115–25.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner